We describe an unusual and interesting case of a full-term infant presenting at 7 days of life with HSV pneumonitis and a tricuspid valve thrombus ultimately requiring extracorporeal membrane oxygenation. The infant subsequently developed a pulmonary embolus. The infant was found to be heterozygous for the prothrombin G20210A mutation and homozygous for the methylenetetrahydrofolate reductase C667T mutation. The patient was treated with low molecular weight heparin for a total of 3 months and has not had a recurrent thrombosis. This case illustrates that a combination of congenital and acquired thrombophilic risk factors can contribute to a significant thrombotic event.
A 7-day-old infant Caucasian girl was referred to our institution for acute respiratory distress requiring intubation. She was a full-term infant with a birth weight of 2900 g. The mother reported no complications with the pregnancy, and the infant had been at home for the past 6 days breastfeeding without difficulty. On the day of admission, the infant exhibited increased sleepiness, poor feeding, pallor and labored breathing. At an outside hospital, she was noted to have respiratory distress and bilateral pulmonary infiltrates on chest X-ray (CXR). The infant was admitted to the intensive-care unit for management, and 12 hours after admission required intubation and mechanical ventilation. After intubation, she was persistently hypoxemic and was transferred to our facility for further treatment. En route she was hypotensive and remained hypoxemic despite antibiotics, acyclovir, inotropic support and ventilation with 100% FiO2.
On presentation, the patient had a coagulopathy with a platelet count of 50,000/mm 3 (normal 150,000 to 450,000/mm 3 ), PTT 77.1 seconds (normal 25 to 32.6 seconds) and INR 2.3. D-dimers were elevated at 0.8 to 1.6 mg/ml (normal <0.2 mg/ml) and fibrinogen was low at 49 mg/dl (normal 150 to 450 mg/dl). This was easily corrected with fresh-frozen plasma and cryoprecipitate. Her liver function was within normal limits. Evaluation of the infant for sepsis included cultures of blood, urine, sputum and cerebrospinal fluid (CSF) and herpes simplex virus (HSV) polymerase chain reaction (PCR) of the CSF. She was treated with cefotaxime, vancomycin and acyclovir. Two sputum cultures grew HSV (type II). The other cultures and the CSF HSV PCR were negative. An echocardiogram (ECHO) was obtained because of suspicion of pulmonary hypertension. Pulmonary arterial pressures were systemic and tricuspid regurgitation was present. Unexpectedly, the ECHO showed a 4 Â 7 mm mass on the anterior leaflet of the tricuspid valve. At 24 hours after initial presentation, the infant required venoarterial (VA) extracorporeal membrane oxygenation (ECMO) for progressive respiratory compromise. On hospital day 5, a bronchoscopy showed inflamed airways consistent with pneumonitis. On hospital day 7, a CXR showed worsening bilateral opacities with a possible wedge-shaped pulmonary infiltrate in the right middle lobe. Repeat ECHO at that time showed no evidence of the tricuspid valve thrombosis. It was suspected that the infant had a pulmonary embolus from the right atrial thrombus. However, since she was supported on VA ECMO, her only clinical signs were hemodynamic instability and worsening chest radiograph. By hospital day 11, her hemodynamic status had improved and she was taken off ECMO. Owing to the previous thromboembolic event, she was started on the standard dose of low molecular weight heparin (LMWH) on hospital day 12. The standard dose of LMWH for infants less than 2 months is 1.5 mg/kg per dose given subcutaneously every 12 hours with a target antifactor Xa level of 0.5 to 1.0 U/ml. 1 On hospital day 14, the infant was weaned completely off inotropic support and extubated. Shortly thereafter, she was transferred out of intensive care. She was ultimately discharged home to complete a 3-month course of LMWH. In addition, she was treated for a total of 21 days with intravenous acyclovir followed by a 6-month course of oral acyclovir. At 3 months after discharge, she had a normal ECHO.
Owing to the unusual complication of an intra-atrial thrombus, a work-up for inherited risk factors for thrombosis was performed. The evaluation included antithrombin activity, protein C activity, protein S free antigen level, methylenetetrahydrofolate reductase (MTHFR) mutation, prothrombin (PT) G20210A mutation and the factor V Leiden mutation. Testing for antiphospholipid antibodies was not performed, as the phospholipid-dependent clotting assays were already abnormal due to the underlying coagulopathy. She was homozygous for the MTHFR mutation and heterozygous for the PT G20210A mutation. The other studies were normal. A review of the family history revealed cerebrovascular accidents and pulmonary embolus on the maternal side. The parents themselves had no history of thromboembolic events. The mother was found to be homozygous for the MTHFR mutation.
DISCUSSION
The first report of a newborn with intracardiac thrombi was in 1935.
1,2 Complications of intracardiac thrombi include infection, cardiac compromise, valvular incompetence 3 and microemboli causing cerebrovascular accidents or pulmonary emboli. Pulmonary emboli in children are rare (1.2 to 7.8 per 10,000 hospital admissions), but should be considered in children with unexplained cyanosis, tachycardia, chest pain or respiratory distress.
Intracardiac thrombi are associated with predisposing conditions including central venous catheters (CVC), congenital heart disease, total parenteral nutrition, polycythemia and respiratory distress syndrome. Other associations have included rheumatic heart disease, 4 Wilms' tumor, 5 hypoxia 6 and disseminated intravascular coagulation. There are a few reports of children with tricuspid valve thrombi with structurally normal hearts. [7] [8] [9] There are four reports of children with intracardiac thrombi and congenital or acquired protein C deficiency as the only predisposing factor. 3, 8, 10, 11 . One child was subsequently found to also have factor V Leiden mutation and high factor VIII levels. 12 To our knowledge, the only case of a child with intracardiac thrombosis and the PT G20210A gene mutation was a 16-year old with Behcet's disease. 13 On presentation, our patient's only known risk factor was sepsis/ pneumonitis. Therefore, a search was undertaken for congenital or acquired thrombophilia. As described, this patient was homozygous for the C667T allele of MTHFR and heterozygous for the PT G20210A mutation.
The C667T allele of MTHFR encodes a thermolabile variant of MTHFR that has decreased activity and is associated with hyperhomocysteinemia. In children, homozygosity for this allele may not be independently associated with increased risk of thrombosis, but may act synergistically with other congenital or acquired risk factors.
14 Hyperhomocysteinemia and homozygous thermolabile MTHFR have been associated with several neonatal thrombotic complications including cerebral vascular accident and inferior venacaval, renal vein and sinovenous thrombosis. [15] [16] [17] [18] [19] A G to A transition at position 20210 in the 3 0 -untranslated region of the PT gene is a risk factor for venous thrombosis. 20 There are a number of reported cases of children, 18 years or younger, with a thrombotic event associated with homozygous or heterozygous PT G20210A. 15,21 -23 In addition, there are numerous reports of PT G20210A in combination with another risk factor contributing to thrombophilia. 22, 24 Treatment of intracardiac thrombi has included surgical intervention, antiplatelet agents, thrombolytics and anticoagulants. In the neonatal period, surgery and thrombolytics are generally reserved for life-threatening thrombi. Also, heparin is preferred to coumadin due to administration, drug interactions, monitoring and safety issues. 25 LMWH is a convenient form of heparin that requires less monitoring and may be administered at home. Complications of LMWH may include hemorrhage, pain/erythema at the injection site, thrombocytopenia, elevated liver function tests and peripheral edema. In addition, care must be taken if the infant has renal failure, because LMWH is cleared by the kidneys. There are no specific dosage adjustments in renal failure, but the anti-Xa level should be more closely monitored. Contraindications of therapy include active bleeding, sensitivity to LMWH or heparin and thrombocytopenia associated with LMWH.
At this time there is no evidence that it is necessary to provide long-term prophylactic anticoagulant treatment for most children with inherited thrombophilia, even if they have experienced a thrombotic event. However, we recommend a comprehensive evaluation of any infant with a thrombotic event, looking for acquired as well as inherited risk factors. This evaluation, based on published epidemiological studies to date, should include plasmabased assays of protein C activity, free protein S antigen, antithrombin activity and antiphospholipid antibodies. DNA testing should screen for factor V Leiden, PT G20210A and homozygosity for the C677T allele of MTHFR. If a congenital prothrombotic disorder is found, then preventive measures including prophylactic anticoagulation can be made in the presence of an acquired risk factor such as immobilization, trauma, sepsis, pregnancy, dehydration, cancer or a CVC. 26 This case illustrates that a combination of congenital and acquired risk factors can contribute to a significant thrombotic event. This case also demonstrates that cardiac valve thrombosis may occur in the absence of a CVC or congenital heart disease. This diagnosis should be considered in infants with cardiac or respiratory compromise and as an etiology of pulmonary embolus.
